Compare AbCellera Biologics Inc (ABCL) vs Amplify Cybersecurity ETF (HACK) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

HACK trades at $110.27, up 3.08% with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF benefits from growing sector spending exceeding $300 billion in 2026, with recent partnerships expanding market reach. Technical indicators show strong trend strength while oscillators suggest potential near-term consolidation.

The outlook remains positive given cybersecurity's essential role in AI adoption, though elevated RSI levels indicate near-term overbought conditions. Key risks include sector competition and market volatility, while institutional momentum supports continued growth potential in the expanding cybersecurity market.